Plus, news about Aquestive Therapeutics and Cybin:
AbbVie enlists Parvus Therapeutics for IBD pact:
AbbVie will have the option to develop and commercialize Parvus’ therapies for inflammatory bowel diseases (IBD). Parvus’ therapies trigger T cells to grow and turn into regulatory T cells — a specialized type of T cell that can suppress the immune system.
The
deal
adds another pipeline option to AbbVie’s IBD franchise, which includes Rinvoq and Skyrizi. And it adds to Parvus’ list of pharma collaborators, which include Novartis and Roche’s Genentech. Financial details of the licensing deal were not disclosed, though Parvus could receive a potential equity investment from AbbVie.
— Lei Lei Wu
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.